Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 166 to 180 of 721 results for must

  1. Normothermic extracorporeal preservation of hearts for transplantation following donation after brainstem death (HTG404)

    Evidence-based recommendations on normothermic extracorporeal preservation of hearts for transplant after brainstem death. This technique is used to store a donor heart for longer before being transplanted.

  2. Free-functioning gracilis transfer to restore upper limb function in brachial plexus injury (HTG568)

    Evidence-based recommendations on free-functioning gracilis transfer to restore upper limb function in brachial plexus injury in adults. This involves taking a piece of hamstring muscle and its nerve and blood supply from the inner thigh, transferring it to the arm and joining it to the damaged nerve.

  3. AccuVein AV400 for vein visualisation (MIB6)

    NICE has developed a Medtech Innovation Briefing (MIB) on the AccuVein AV400 for vein visualisation

  4. Nivolumab for treating advanced (unresectable or metastatic) melanoma (TA384)

    Evidence-based recommendations on nivolumab (Opdivo) for treating advanced (unresectable or metastatic) melanoma in adults.

  5. Who can register as a stakeholder?

    Find out more about the types of organisations that can register to be a stakeholder at NICE.

  6. Making decisions using NICE guidelines

    People have the right to be able to make informed decisions about their care. Our guidance should be taken into account when making decisions with them.

  7. Who can register as a stakeholder?

    Find out more about the types of organisations that can register to be a stakeholder at NICE.

  8. Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer (TA263)

    Evidence-based recommendations on bevacizumab (Avastin), with capecitabine, for treating metastatic breast cancer in adults.

  9. Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma (TA268)

    Evidence-based recommendations on ipilimumab (Yervoy) for previously treated advanced melanoma in adults.

  10. Percutaneous endoscopic colostomy (HTG105)

    Evidence-based recommendations on percutaneous endoscopic colostomy. This involves placing a plastic tube in the bowel that runs back through a small opening in the abdomen to allow waste to pass through to a drainage bag worn outside the body.

  11. OpenAthens registration help

    Help with registering for your NHS OpenAthens account.

  12. Single-step scaffold insertion for repairing symptomatic chondral knee defects (HTG728)

    Evidence-based recommendations on single-step scaffold insertion for repairing symptomatic chondral knee defects. This involves inserting a scaffold into the damaged area of the knee to support regrowth and repair of the cartilage.

  13. Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer (CG164)

    This guideline covers care for people with a family history of breast, ovarian or another related (prostate or pancreatic) cancer. It aims to improve the long-term health of these families by describing strategies to reduce the risk of and promote early detection of breast cancer (including genetic testing and mammography). It also includes advice on treatments (tamoxifen, raloxifene) and surgery (mastectomy).

  14. Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab (TA357)

    Evidence-based recommendations on pembrolizumab (Keytruda) for treating advanced melanoma after disease progression with ipilimumab in adults.

  15. Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer (TA285)

    Evidence-based recommendations on bevacizumab (Avastin), with gemcitabine and carboplatin, for treating platinum-sensitive advanced ovarian cancer in adults.